BBHC
ACAD icon

Brown Brothers Harriman & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-106
Closed -$3K – 792
2017
Q4 		$3K Buy
+106
New +$3.39K ﹤0.01% 926
2017
Q1 		– Sell
-110
Closed -$3K – 790
2016
Q4 		$3K Hold
110
– – ﹤0.01% 808
2016
Q3 		$3K Hold
110
– – ﹤0.01% 724
2016
Q2 		$4K Buy
+110
New +$3.68K ﹤0.01% 727

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Brown Brothers Harriman & Co's ACAD Position: Q1 2018 in Review

Brown Brothers Harriman & Co sold out of Acadia Pharmaceuticals (ACAD) in Q1 2018, closing a stake of 106 shares — an estimated $3K sold.

Brown Brothers Harriman & Co first reported a position in ACAD in Q2 2016 and held it in 4 quarters. The position peaked at $4K in Q2 2016. 196 funds tracked by Wall St. Rank hold ACAD as of Q1 2018.

  • Brown Brothers Harriman & Co reported no remaining Acadia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 106 Acadia Pharmaceuticals shares in Q1 2018, an estimated $3K.
  • Brown Brothers Harriman & Co first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Brown Brothers Harriman & Co's Acadia Pharmaceuticals position peaked at $4K in Q2 2016.
  • 196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2018.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2018, filed 14 May 2018.